BRISTOL-MYERS SQUIBB COMPANY Proceeds from Issuance of Debt
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Proceeds from Issuance of Debt of $12.88 billion for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2024-10-31
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of debt for the quarter ending 2024-09-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of debt for the quarter ending 2024-06-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of debt for the quarter ending 2024-03-31 was $12.88B.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of debt for the quarter ending 2023-09-30 was $0.00.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month |
|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $12.88B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-26 | $12.88B 10-Q · filed 2024-07-26 | |
| 2024-03-31 | $12.88B 10-Q · filed 2024-04-25 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-26 | $0.00 10-Q · filed 2024-07-26 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-04-25 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $0.00 derived: sum of 2 quarters · filed 2023-10-26 | $5.93B 10-Q · filed 2023-10-26 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-27 | $5.93B 10-Q · filed 2023-07-27 | |
| 2022-03-31 | $5.93B 10-Q · filed 2023-04-27 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | $0.00 derived: sum of 2 quarters · filed 2022-10-26 | $0.00 10-Q · filed 2022-10-26 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $0.00 10-Q · filed 2022-07-27 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-04-29 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $18.79B 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $18.79B 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |